DGIdb - PTEN Gene Record

PTEN 5728 Clinically ActionableDrug Resistance

Alternate Names:

5728
PHOSPHATASE AND TENSIN HOMOLOG
PTEN
10q23del
BZS
CWS1
DEC
GLM2
MHAM
MMAC1
PTEN1
PTENbeta
TEP1
601728
9588
ENSG00000171862
OTTHUMG00000018688
P60484
41
PA33942
Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN

Gene Info:

Gene Biotype	PROTEIN_CODING

(13 More Sources)

Gene Categories: Category Details

PROTEIN PHOSPHATASE
KINASE
DRUG RESISTANCE
PTEN FAMILY
CLINICALLY ACTIONABLE
ENZYME

Publications:

Myers et al., 2016, Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study., Gynecol. Oncol.
Weigelt et al., 2013, PI3K pathway dependencies in endometrioid endometrial cancer cell lines., Clin. Cancer Res.
Neshat et al., 2001, Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR., Proc. Natl. Acad. Sci. U.S.A.
Yuan et al., 2011, PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity., Mol. Cancer Ther.
Davies et al., 2012, Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background., Mol. Cancer Ther.
De Velasco et al., 2016, Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer., Oncotarget
Liu et al., 2013, Targeting SRC and tubulin in mucinous ovarian carcinoma., Clin. Cancer Res.
Lin et al., 2013, Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models., Clin. Cancer Res.
Yan et al., 2013, Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068., Clin. Cancer Res.
Saura et al., 2017, A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors., Cancer Discov
de Bono JS et al., 2019, Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss., Clin Cancer Res
Patnaik et al., 2016, First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas., Ann. Oncol.
Muh et al., 2014, PTEN status mediates 2ME2 anti-tumor efficacy in preclinical glioblastoma models: role of HIF1α suppression., J. Neurooncol.
Yang et al., 2016, Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer., Clin. Cancer Res.
Sartore-Bianchi et al., 2009, PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies., Cancer Res.
De Roock et al., 2011, KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer., Lancet Oncol.
Mallon et al., 2010, Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor., Mol. Cancer Ther.
Di Nicolantonio et al., 2010, Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus., J. Clin. Invest.
Mohseni et al., 2010, PIK3CA and KRAS mutations predict for response to everolimus therapy: now that's RAD001., J. Clin. Invest.
Seront et al., 2012, Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers., Ann. Oncol.
Kim et al., 2017, Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy., BMC Cancer
Powles et al., 2016, Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma., J. Clin. Oncol.
Shoji et al., 2012, Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas., PLoS ONE
Weigelt et al., 2011, PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs., Oncogene
André et al., 2016, Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3., J. Clin. Oncol.
Seront et al., 2013, PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation., Br. J. Cancer
Templeton et al., 2013, Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08)., Eur. Urol.
Liu et al., 2016, High Sensitivity of an Ha-RAS Transgenic Model of Superficial Bladder Cancer to Metformin Is Associated with ∼240-Fold Higher Drug Concentration in Urine than Serum., Mol. Cancer Ther.
Iglesias et al., 2013, Another surprise from Metformin: novel mechanism of action via K-Ras influences endometrial cancer response to therapy., Mol. Cancer Ther.
Zumsteg et al., 2016, Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations., Clin. Cancer Res.
Kashiyama et al., 2014, Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423., PLoS ONE
Lee et al., 2015, A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients., Clin. Cancer Res.
García-García et al., 2015, MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer., Clin. Cancer Res.
Herkert et al., 2016, Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition., Cancer Res.
Shi H et al., 2014, Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy., Cancer Discov
Feng et al., 2016, A Novel Plant Sesquiterpene Lactone Derivative, DETD-35, Suppresses BRAFV600E Mutant Melanoma Growth and Overcomes Acquired Vemurafenib Resistance in Mice., Mol. Cancer Ther.
Bonnevaux et al., 2016, Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor., Mol. Cancer Ther.
Van Allen et al., 2014, The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma., Cancer Discov
Shi et al., 2014, A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition., Cancer Discov
Yahiaoui et al., 2017, PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors., PLoS ONE
Packer et al., 2017, PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2(mutant) Endometrial Cancers., Mol. Cancer Ther.
Raja et al., 2015, Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer., Mol. Cancer Ther.
Angevin et al., 2017, Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study., Eur. J. Cancer
Kampa-Schittenhelm et al., 2013, Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia., Mol. Cancer
Schwartz et al., 2015, Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ., Cancer Cell
Juric et al., 2015, Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor., Nature
Le et al., 2016, Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer., Cancer Discov
Costa et al., 2015, Discovery and functional characterization of a neomorphic PTEN mutation., Proc. Natl. Acad. Sci. U.S.A.
Mellinghoff et al., 2005, Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors., N. Engl. J. Med.
Ma et al., 2016, InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma., Clin. Cancer Res.
Yap et al., 2011, Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930., Mol. Cancer Ther.
Qian et al., 2012, Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling., Clin. Cancer Res.
Karpel-Massler et al., 2015, TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo., Oncotarget
Wang et al., 2011, PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib., BMC Cancer
Berns et al., 2007, A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer., Cancer Cell
Saura et al., 2014, Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy., Clin. Cancer Res.
Fujita et al., 2006, PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer., Br. J. Cancer
Nagata et al., 2004, PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients., Cancer Cell
Esteva et al., 2010, PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer., Am. J. Pathol.
Byron et al., 2012, Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status., Mol. Cancer
Foster et al., 2015, The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models., Mol. Cancer Ther.
Thanapprapasr et al., 2015, PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer., Mol. Cancer Ther.
Hyman et al., 2015, Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors., Cancer Chemother. Pharmacol.
Smith et al., 2016, Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth., Mol. Cancer Ther.
Machl et al., 2016, M2698 is a potent dual-inhibitor of p70S6K and Akt that affects tumor growth in mouse models of cancer and crosses the blood-brain barrier., Am J Cancer Res
Poklepovic et al., 2016, Phase I study of pemetrexed with sorafenib in advanced solid tumors., Oncotarget
Yap et al., 2015, Drugging PI3K in cancer: refining targets and therapeutic strategies., Curr Opin Pharmacol
Peng et al., 2016, Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy., Cancer Discov
Salphati et al., 2016, Brain Distribution and Efficacy of the Brain Penetrant PI3K Inhibitor GDC-0084 in Orthotopic Mouse Models of Human Glioblastoma., Drug Metab. Dispos.
Bhagwat et al., 2011, Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin., Mol. Cancer Ther.
Anderson et al., 2016, PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation., Sci Transl Med
Zhao J et al., 2019, Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma., Nat Med
Vansteenkiste et al., 2015, Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study., J Thorac Oncol
Barlaam et al., 2015, Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3Kβ and PI3Kδ for the treatment of PTEN-deficient cancers., J. Med. Chem.
Weekes et al., 2013, Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer., Clin. Cancer Res.
Depreeuw et al., 2015, Characterization of patient-derived tumor xenograft models of endometrial cancer for preclinical evaluation of targeted therapies., Gynecol. Oncol.
Zhao et al., 2004, PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells., Oncogene
Mallon et al., 2011, Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor., Clin. Cancer Res.
Hollestelle et al., 2007, Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines., Mol. Cancer Res.
Hassan et al., 2014, Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors., Oncotarget
Hudson et al., 2016, Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers., Mol. Cancer Ther.
Zahonero et al., 2015, Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma., Mol. Cancer Ther.
Venkatesan et al., 2010, PKI-179: an orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor., Bioorg. Med. Chem. Lett.
Shen et al., 2013, BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency., Clin. Cancer Res.
Tanaka et al., 2011, The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations., Clin. Cancer Res.
Swick et al., 2017, Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC., Mol. Cancer Ther.
Guzeloglu-Kayisli et al., 2003, Regulation of PTEN (phosphatase and tensin homolog deleted on chromosome 10) expression by estradiol and progesterone in human endometrium., J. Clin. Endocrinol. Metab.
Gupta et al., 2015, A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies., Clin. Cancer Res.
Yap et al., 2011, First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors., J. Clin. Oncol.
Liu et al., 2011, The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway., J. Clin. Endocrinol. Metab.
Chatterjee et al., 2013, PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells., PLoS ONE
Vlietstra et al., 1998, Frequent inactivation of PTEN in prostate cancer cell lines and xenografts., Cancer Res.
Hart et al., 2013, VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer., Mol. Cancer Ther.
McCabe et al., 2015, Mechanistic Rationale to Target PTEN-Deficient Tumor Cells with Inhibitors of the DNA Damage Response Kinase ATM., Cancer Res.
Yu et al., 2014, Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway., Mol. Cancer Ther.
Hoeflich et al., 2009, Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression., Cancer Res.
Spoerke et al., 2012, Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models., Clin. Cancer Res.
Cheng et al., 2014, A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition., Cancer Res.
Herrera-Abreu et al., 2016, Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer., Cancer Res.
Stratikopoulos et al., 2015, Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy., Cancer Cell
Yap et al., 2012, AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity., Clin. Cancer Res.
Jalota-Badhwar et al., 2015, P7170: A Novel Molecule with Unique Profile of mTORC1/C2 and Activin Receptor-like Kinase 1 Inhibition Leading to Antitumor and Antiangiogenic Activity., Mol. Cancer Ther.
Bendell et al., 2015, A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma., Cancer
Certal et al., 2014, Discovery and optimization of pyrimidone indoline amide PI3Kβ inhibitors for the treatment of phosphatase and tensin homologue (PTEN)-deficient cancers., J. Med. Chem.

ENZALUTAMIDE PTEN

Interaction Score: 0.96

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy AZD8186 + Enzalutamide

Evidence Type Actionable

Approval Status Preclinical

PMIDs:
25544636

Sources:
JAX-CKB CIViC
KU-55933 PTEN

Interaction Score: 0.64

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type colon cancer

Response Type sensitive

Approval Status Preclinical

PMIDs:
25870146

Sources:
JAX-CKB
GSK-2256098 PTEN

Interaction Score: 0.64

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type uterine cancer

Response Type decreased response

Approval Status Preclinical

PMIDs:
25833835

Sources:
JAX-CKB
CHEMBL263664 PTEN

Interaction Score: 0.64

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell line xenograft

Response Type sensitive

PMIDs:
21191045

Sources:
JAX-CKB
IPATASERTIB PTEN

Interaction Score: 0.55

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Ipatasertib + Paclitaxel

Indication/Tumor Type triple-receptor negative breast cancer

Response Type predicted – sensitive

PMIDs:
23287563 24141624 27872130 30037818

Sources:
JAX-CKB CIViC
AZD-8186 PTEN

Interaction Score: 0.51

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy AZD8186 + BYL719

combination therapy AZD8186 + Enzalutamide

combination therapy AZD8186 + BYL719 + Enzalutamide

PMIDs:
25544636 25514658

Sources:
JAX-CKB OncoKB
SAR-260301 PTEN

Interaction Score: 0.48

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type melanoma

Response Type sensitive

Approval Status Preclinical - Cell line xenograft

PMIDs:
27196754 24387221

Sources:
JAX-CKB
AZD-8835 PTEN

Interaction Score: 0.42

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type breast cancer

Response Type resistant

Approval Status Preclinical

PMIDs:
26839307

Sources:
JAX-CKB
KX2-391 PTEN

Interaction Score: 0.42

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type ovarian mucinous neoplasm

Response Type decreased response

Approval Status Preclinical

PMIDs:
24100628

Sources:
JAX-CKB
BGT-226 PTEN

Interaction Score: 0.42

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell culture

Response Type sensitive

PMIDs:
23705826

Sources:
JAX-CKB
CHEMBL1765740 PTEN

Interaction Score: 0.42

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell culture

Response Type predicted – sensitive

PMIDs:
28178345

Sources:
JAX-CKB
DACOMITINIB PTEN

Interaction Score: 0.38

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy BMS-754807 + Dacomitinib

Indication/Tumor Type glioblastoma multiforme

Response Type sensitive

PMIDs:
25939761 26561558

Sources:
JAX-CKB
CC-223 PTEN

Interaction Score: 0.32

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type sensitive

Approval Status Phase I

PMIDs:
26177599

Sources:
JAX-CKB
IDELALISIB PTEN

Interaction Score: 0.32

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Idelalisib + MK2206

Indication/Tumor Type diffuse large B-cell lymphoma

Response Type predicted – sensitive

PMIDs:
28178345

Sources:
JAX-CKB
PKI-179 PTEN

Interaction Score: 0.32

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type prostate cancer

Response Type sensitive

Approval Status Preclinical - Cell culture

PMIDs:
20797855

Sources:
JAX-CKB
CHEMBL589258 PTEN

Interaction Score: 0.32

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell line xenograft

Response Type sensitive

PMIDs:
20371716

Sources:
JAX-CKB
CAPIVASERTIB PTEN

Interaction Score: 0.28

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type sensitive

Approval Status Preclinical - Cell culture

PMIDs:
22294718 26910118

Sources:
JAX-CKB CIViC
GSK-2636771 PTEN

Interaction Score: 0.28

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

combination therapy GSK2636771 + LGX818

Indication/Tumor Type melanoma

Response Type no benefit

PMIDs:
26117819 26645196 23674493 26577700

Sources:
JAX-CKB MyCancerGenomeClinicalTrial OncoKB
PICTILISIB PTEN

Interaction Score: 0.25

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy GDC-0941 + MS417

Indication/Tumor Type breast cancer

Response Type predicted – sensitive

PMIDs:
9661880 22693356 19276360 24265153 23136191 24322983 27020857 26577700 26733612 28119489 26058079

Sources:
JAX-CKB
ONC-201 PTEN

Interaction Score: 0.25

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Navitoclax + ONC201

Indication/Tumor Type glioblastoma multiforme

Response Type sensitive

PMIDs:
26474387

Sources:
JAX-CKB
ABT 737 PTEN

Interaction Score: 0.25

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy ABT-737 + BEZ235

Evidence Type Actionable

Approval Status Preclinical - Cell line xenograft

PMIDs:
27974663

Sources:
JAX-CKB
TEMSIROLIMUS PTEN

Interaction Score: 0.25

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type endometrial cancer

Response Type no benefit

Approval Status Phase II

PMIDs:
27016228 23674493 11504908

Sources:
ClearityFoundationBiomarkers JAX-CKB CIViC
TRASTUZUMAB PTEN

Interaction Score: 0.24

Interaction Types & Directionality:

n/a

Interaction Info:

Approval Status Clinical Study

Response Type decreased response

Evidence Type Actionable

PMIDs:
21676217 17936563 24470511 16404430 15324695 20813970

Sources:
JAX-CKB CIViC
MK-2206 PTEN

Interaction Score: 0.22

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type follicular thyroid carcinoma

Response Type sensitive

Approval Status Preclinical - Cell culture

PMIDs:
28178345 26187616 22025163 24265152 21289267

Sources:
JAX-CKB
AEW-541 PTEN

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy AZD6482 + NVP-AEW541

Indication/Tumor Type melanoma

Response Type no benefit

PMIDs:
26577700

Sources:
JAX-CKB
UPROSERTIB PTEN

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type melanoma

Response Type sensitive

Approval Status Preclinical - Cell culture

PMIDs:
24265152

Sources:
JAX-CKB
MSC-2363318A PTEN

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type triple-receptor negative breast cancer

Response Type sensitive

Approval Status Preclinical - Cell line xenograft

PMIDs:
27186432

Sources:
JAX-CKB
ACALISIB PTEN

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell line xenograft

Response Type sensitive

PMIDs:
None found

Sources:
JAX-CKB
AZD-6482 PTEN

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy AZD6482 + Niraparib

combination therapy AZD6482 + Talazoparib

combination therapy AZD6482 + Olaparib

PMIDs:
23674493 26577700 26504226

Sources:
JAX-CKB
EVEROLIMUS PTEN

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type breast cancer

Response Type sensitive

Approval Status Preclinical - Cell culture

PMIDs:
20664172 20664174 22473592 28330462 26951309 22662154 21358673 27091708 23989949 23582881

Sources:
ClearityFoundationBiomarkers JAX-CKB CIViC
AT-13148 PTEN

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type uterine corpus sarcoma

Response Type sensitive

Approval Status Preclinical - Cell line xenograft

PMIDs:
22781553

Sources:
JAX-CKB
LINSITINIB PTEN

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Gefitinib + Linsitinib

Indication/Tumor Type glioblastoma multiforme

Response Type sensitive

PMIDs:
26561558

Sources:
JAX-CKB
REFAMETINIB PTEN

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type ocular melanoma

Response Type predicted – sensitive

Approval Status Phase I

PMIDs:
23434733

Sources:
JAX-CKB
E-6201 PTEN

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

Response Type decreased response

Approval Status Preclinical - Cell line xenograft

Evidence Type Actionable

PMIDs:
23039341

Sources:
JAX-CKB
ALPELISIB PTEN

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type prostate cancer

Response Type sensitive

Approval Status Preclinical - Cell culture

PMIDs:
25544636 25409150 27604488 26577700 28119489 26504226

Sources:
ClearityFoundationBiomarkers JAX-CKB CIViC
TASELISIB PTEN

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

Approval Status Preclinical

Evidence Type Actionable

Approval Status Preclinical - Cell line xenograft

PMIDs:
26589432

Sources:
JAX-CKB CIViC
NIVOLUMAB PTEN

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type melanoma

Response Type sensitive

Approval Status Clinical Study

PMIDs:
26645196 30742119

Sources:
JAX-CKB CIViC
BUPARLISIB PTEN

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy BKM120 + Trastuzumab

Indication/Tumor Type Her2-receptor positive breast cancer

Response Type predicted – sensitive

PMIDs:
26098748 28119489 24470511 25672916

Sources:
JAX-CKB CIViC
ENCORAFENIB PTEN

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy GSK2636771 + LGX818

Indication/Tumor Type melanoma

Response Type no benefit

PMIDs:
26577700

Sources:
JAX-CKB
DS-7423 PTEN

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type ovarian clear cell adenocarcinoma

Response Type sensitive

Approval Status Preclinical - Cell line xenograft

PMIDs:
24504419

Sources:
ClearityFoundationBiomarkers JAX-CKB
VEMURAFENIB PTEN

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy DETD-35 + Vemurafenib

Approval Status Preclinical - Cell line xenograft

combination therapy SAR260301 + Vemurafenib

PMIDs:
24265155 27048951 27196754 24265153 24265152

Sources:
JAX-CKB CIViC
RG-7666 PTEN

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type glioblastoma multiforme

Response Type sensitive

Approval Status Preclinical - Cell line xenograft

PMIDs:
27638506

Sources:
JAX-CKB
PLX-4720 PTEN

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy GDC-0941 + PLX4720

Indication/Tumor Type melanoma

Response Type sensitive

PMIDs:
24265153

Sources:
JAX-CKB
ABIRATERONE PTEN

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Abiraterone + Ipatasertib

Indication/Tumor Type prostate cancer

Response Type sensitive

PMIDs:
None found

Sources:
JAX-CKB
OSI-027 PTEN

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type breast cancer

Response Type sensitive

Approval Status Preclinical - Cell line xenograft

PMIDs:
21673091

Sources:
JAX-CKB
SAMOTOLISIB PTEN

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type glioblastoma multiforme

Evidence Type Actionable

Approval Status Preclinical - Cell line xenograft

PMIDs:
27439478

Sources:
JAX-CKB
2-METHOXYESTRADIOL PTEN

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type glioblastoma multiforme

Response Type sensitive

Approval Status Preclinical

PMIDs:
24162827

Sources:
JAX-CKB
SAPANISERTIB PTEN

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy MLN0128 + PD-0325901

Indication/Tumor Type colorectal cancer

Response Type no benefit

PMIDs:
27974663 26272063 25261369

Sources:
JAX-CKB
VENETOCLAX PTEN

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy BEZ235 + Venetoclax

Indication/Tumor Type breast cancer

Response Type no benefit

PMIDs:
27974663

Sources:
JAX-CKB
TALAZOPARIB PTEN

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type sensitive

Approval Status Preclinical

PMIDs:
23881923

Sources:
JAX-CKB
PEMBROLIZUMAB PTEN

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type melanoma

Response Type sensitive

Approval Status Clinical Study

PMIDs:
26645196 30742119

Sources:
JAX-CKB CIViC
PD-0325901 PTEN

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

Response Type no benefit

combination therapy MLN0128 + PD-0325901

Indication/Tumor Type colorectal cancer

PMIDs:
26272063

Sources:
JAX-CKB
COPANLISIB PTEN

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type endometrial carcinoma

Response Type sensitive

Approval Status Phase I

PMIDs:
27672108

Sources:
ClearityFoundationBiomarkers JAX-CKB
PF-04691502 PTEN

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type glioblastoma multiforme

Response Type sensitive

Approval Status Preclinical - Cell line xenograft

PMIDs:
21750219

Sources:
ClearityFoundationBiomarkers JAX-CKB
GEDATOLISIB PTEN

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type breast cancer

Response Type sensitive

Approval Status Preclinical

PMIDs:
14737113 21325073 17314276

Sources:
ClearityFoundationBiomarkers JAX-CKB
PANULISIB PTEN

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type prostate cancer

Response Type sensitive

Approval Status Preclinical - Cell line xenograft

PMIDs:
25700704

Sources:
JAX-CKB
VS-5584 PTEN

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type prostate cancer

Response Type not applicable

Approval Status Preclinical - Cell line xenograft

PMIDs:
23270925

Sources:
JAX-CKB
PA-799 PTEN

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type endometrial cancer

Response Type sensitive

Approval Status Preclinical

PMIDs:
21558396

Sources:
JAX-CKB
NAVITOCLAX PTEN

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Navitoclax + ONC201

Indication/Tumor Type glioblastoma multiforme

Response Type sensitive

PMIDs:
26474387

Sources:
JAX-CKB
BINIMETINIB PTEN

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy BYL719 + MEK162

Indication/Tumor Type melanoma

Response Type no benefit

PMIDs:
26577700 26206338

Sources:
JAX-CKB
DACTOLISIB PTEN

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Selumetinib + BEZ235

Indication/Tumor Type endometrial cancer

Response Type sensitive

PMIDs:
28446642 27974663 26206338 22662154 26232337

Sources:
ClearityFoundationBiomarkers JAX-CKB
BMS-754807 PTEN

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy BMS-754807 + Dacomitinib

Indication/Tumor Type glioblastoma multiforme

Response Type sensitive

PMIDs:
26561558

Sources:
JAX-CKB
FULVESTRANT PTEN

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Fulvestrant + GDC-0941

Indication/Tumor Type estrogen-receptor positive breast cancer

Response Type sensitive

PMIDs:
26733612

Sources:
JAX-CKB
PILARALISIB PTEN

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type glioblastoma multiforme

Response Type sensitive

Approval Status Preclinical - Cell line xenograft

PMIDs:
25637314

Sources:
ClearityFoundationBiomarkers JAX-CKB
PANITUMUMAB PTEN

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19223544

Sources:
ClearityFoundationBiomarkers CIViC
PEMETREXED PTEN

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Pemetrexed + Sorafenib

Indication/Tumor Type Advanced Solid Tumor

Response Type predicted – sensitive

PMIDs:
27213589

Sources:
JAX-CKB
AZD-8055 PTEN

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type head and neck squamous cell carcinoma

Response Type predicted – sensitive

Approval Status Preclinical - Cell culture

PMIDs:
28446642

Sources:
JAX-CKB
TOPOTECAN PTEN

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical

Response Type sensitive

PMIDs:
25833835

Sources:
JAX-CKB
VISTUSERTIB PTEN

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy AZD8186 + Vistusertib

Indication/Tumor Type colorectal cancer

Response Type sensitive

PMIDs:
None found

Sources:
JAX-CKB
SELUMETINIB PTEN

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Selumetinib + BEZ235

Indication/Tumor Type endometrial cancer

Response Type sensitive

PMIDs:
27196754 21358673 26232337

Sources:
JAX-CKB
NIRAPARIB PTEN

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy AZD6482 + Niraparib

Indication/Tumor Type triple-receptor negative breast cancer

Response Type sensitive

PMIDs:
None found

Sources:
JAX-CKB
VOXTALISIB PTEN

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type glioblastoma multiforme

Response Type sensitive

Approval Status Preclinical - Cell line xenograft

PMIDs:
24634413

Sources:
JAX-CKB
TEMOZOLOMIDE PTEN

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Vandetanib + Temozolomide

Indication/Tumor Type glioblastoma multiforme

Response Type no benefit

PMIDs:
25910950

Sources:
JAX-CKB
FIMEPINOSTAT PTEN

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type breast cancer

Response Type sensitive

Approval Status Preclinical - Cell culture

PMIDs:
22693356

Sources:
JAX-CKB
RIGOSERTIB PTEN

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Phase I

Response Type predicted – sensitive

PMIDs:
None found

Sources:
JAX-CKB
VELIPARIB PTEN

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy AZD6482 + Veliparib

Indication/Tumor Type triple-receptor negative breast cancer

Response Type sensitive

PMIDs:
None found

Sources:
JAX-CKB
APITOLISIB PTEN

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type endometrial cancer

Response Type sensitive

Approval Status Phase II

PMIDs:
26951309

Sources:
JAX-CKB
CETUXIMAB PTEN

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19223544 21163703

Sources:
ClearityFoundationBiomarkers CIViC
INFIGRATINIB PTEN

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy BGJ398 + BYL719

Indication/Tumor Type endometrial cancer

Response Type sensitive

PMIDs:
28119489

Sources:
JAX-CKB
METFORMIN PTEN

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

Approval Status Preclinical

Indication/Tumor Type urinary bladder cancer

Evidence Type Actionable

PMIDs:
26921394 24077915

Sources:
JAX-CKB
GEFITINIB PTEN

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Gefitinib + Linsitinib

Indication/Tumor Type glioblastoma multiforme

Response Type sensitive

PMIDs:
16282176 26561558

Sources:
ClearityFoundationBiomarkers JAX-CKB CIViC
VORINOSTAT PTEN

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy GDC-0941 + vorinostat

Indication/Tumor Type prostate cancer

Response Type sensitive

PMIDs:
9661880 22693356

Sources:
JAX-CKB
ERLOTINIB PTEN

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16282176

Sources:
ClearityFoundationBiomarkers CIViC
RUCAPARIB PTEN

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy AZD6482 + Rucaparib

Indication/Tumor Type triple-receptor negative breast cancer

Response Type sensitive

PMIDs:
23565244

Sources:
JAX-CKB
VANDETANIB PTEN

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Phase II

Response Type no benefit

PMIDs:
25910950

Sources:
ClearityFoundationBiomarkers JAX-CKB
OXALIPLATIN PTEN

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy KX2-391 + Oxaliplatin

Indication/Tumor Type ovarian mucinous neoplasm

Response Type sensitive

PMIDs:
24100628

Sources:
JAX-CKB
OMIPALISIB PTEN

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
ClearityFoundationBiomarkers
PACLITAXEL PTEN

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

Approval Status Preclinical - Cell line xenograft

Indication/Tumor Type prostate adenocarcinoma

combination therapy XL147 + Paclitaxel

PMIDs:
25637314 25833835 25672916

Sources:
JAX-CKB CIViC
PALBOCICLIB PTEN

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Palbociclib + GDC-0941

Indication/Tumor Type triple-receptor negative breast cancer

Response Type no benefit

PMIDs:
27020857

Sources:
JAX-CKB
CARBOPLATIN PTEN

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25672916

Sources:
CIViC PharmGKB
OLAPARIB PTEN

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy AZD6482 + Olaparib

Indication/Tumor Type triple-receptor negative breast cancer

Response Type sensitive

PMIDs:
None found

Sources:
JAX-CKB
PROGESTERONE PTEN

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14557489

Sources:
NCI
CAPECITABINE PTEN

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
SORAFENIB PTEN

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Pemetrexed + Sorafenib

Indication/Tumor Type Advanced Solid Tumor

Response Type predicted – sensitive

PMIDs:
27213589

Sources:
JAX-CKB
GEMCITABINE PTEN

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Gemcitabine + LY2780301

Indication/Tumor Type breast adenocarcinoma

Response Type sensitive

PMIDs:
28750271

Sources:
JAX-CKB
FLUOROURACIL PTEN

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
CISPLATIN PTEN

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB

Ensembl: ENSG00000171862
- Version: 101_38
Alternate Names:

PTEN Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:

JAX-CKB: PTEN

Version: 27-September-2017

Alternate Names:

5728 CKB Entrez Id

PTEN CKB Gene Synonym

10q23del CKB Gene Synonym

Gene Info:

Publications:

Myers et al., 2016, Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study., Gynecol. Oncol.

Yuan et al., 2011, PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity., Mol. Cancer Ther.

Patnaik et al., 2016, First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas., Ann. Oncol.

CIViC: PTEN

Version: 14-September-2020

Alternate Names:

5728 Entrez Gene ID

41 CIViC Gene ID

Gene Info:

Gene Categories:

DRUG RESISTANCE

Publications:

Courtney et al., 2010, The PI3K pathway as drug target in human cancer., J. Clin. Oncol.

Mellinghoff et al., 2005, Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors., N. Engl. J. Med.

Seront et al., 2013, PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation., Br. J. Cancer

NCI: PTEN

Version: 14-September-2017

Alternate Names:

Gene Info:

Publications:

Shingu et al., 2003, Growth inhibition of human malignant glioma cells induced by the PI3-K-specific inhibitor., J. Neurosurg.

Guzeloglu-Kayisli et al., 2003, Regulation of PTEN (phosphatase and tensin homolog deleted on chromosome 10) expression by estradiol and progesterone in human endometrium., J. Clin. Endocrinol. Metab.

OncoKB: PTEN
- Version: 23-July-2020
Alternate Names:

5728 OncoKB Entrez Id

DEC OncoKB Gene Synonym

MHAM OncoKB Gene Synonym

Gene Info:

Publications:
PharmGKB: PTEN
- Version: 18-August-2020
Alternate Names:

PA33942 PharmGKB ID

Gene Info:

Publications:
HumanProteinAtlas: PTEN
- Version: 19.3
Alternate Names:

ENSG00000171862 Ensembl Gene ID

BZS Human Protein Atlas Gene Synonym

MHAM Human Protein Atlas Gene Synonym

Gene Info:

Gene Categories:

ENZYME

Publications:
GO: PTEN
- Version: 01-February-2022
Alternate Names:

MMAC1 GO Gene Synonym

TEP1 GO Gene Synonym

Gene Info:

Gene Categories:

PROTEIN PHOSPHATASE

Publications:
Tempus: PTEN
- Version: 11-November-2018
Alternate Names:

PTEN Gene Symbol

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
dGene: PTEN
- Version: 27-Jun-2013
Alternate Names:

5728 Gene ID

10q23del dGene Synonym

BZS dGene Synonym

Gene Info:

Gene Categories:

PTEN FAMILY

Publications:
Pharos: PTEN
- Version: 01-February-2022
Alternate Names:

Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Gene Name

P60484 UniProt ID

Gene Info:

Gene Categories:

KINASE

Publications:
MskImpact: PTEN
- Version: May-2015
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
MyCancerGenomeClinicalTrial: PTEN
- Version: 30-February-2014
Alternate Names:

Gene Info:

Publications:
ClearityFoundationBiomarkers: PTEN
- Version: 26-July-2013
Alternate Names:

Gene Info:

Publications:
FoundationOneGenes: PTEN
- Version: 03-September-2020
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
CarisMolecularIntelligence: PTEN
- Version: 04-September-2020
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
Oncomine: PTEN
- Version: v3
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:

combination therapy	AZD8186 + Enzalutamide
Evidence Type	Actionable
Approval Status	Preclinical

Indication/Tumor Type	colon cancer
Response Type	sensitive
Approval Status	Preclinical

Indication/Tumor Type	uterine cancer
Response Type	decreased response
Approval Status	Preclinical

combination therapy	Ipatasertib + Paclitaxel
Indication/Tumor Type	triple-receptor negative breast cancer
Response Type	predicted – sensitive

combination therapy	AZD8186 + BYL719
combination therapy	AZD8186 + Enzalutamide
combination therapy	AZD8186 + BYL719 + Enzalutamide

Indication/Tumor Type	melanoma
Response Type	sensitive
Approval Status	Preclinical - Cell line xenograft

Indication/Tumor Type	breast cancer
Response Type	resistant
Approval Status	Preclinical

Indication/Tumor Type	ovarian mucinous neoplasm
Response Type	decreased response
Approval Status	Preclinical

combination therapy	BMS-754807 + Dacomitinib
Indication/Tumor Type	glioblastoma multiforme
Response Type	sensitive

Indication/Tumor Type	Advanced Solid Tumor
Response Type	sensitive
Approval Status	Phase I

combination therapy	Idelalisib + MK2206
Indication/Tumor Type	diffuse large B-cell lymphoma
Response Type	predicted – sensitive

Indication/Tumor Type	prostate cancer
Response Type	sensitive
Approval Status	Preclinical - Cell culture

combination therapy	GSK2636771 + LGX818
Indication/Tumor Type	melanoma
Response Type	no benefit

combination therapy	GDC-0941 + MS417
Indication/Tumor Type	breast cancer
Response Type	predicted – sensitive

combination therapy	Navitoclax + ONC201
Indication/Tumor Type	glioblastoma multiforme
Response Type	sensitive

combination therapy	ABT-737 + BEZ235
Evidence Type	Actionable
Approval Status	Preclinical - Cell line xenograft

Indication/Tumor Type	endometrial cancer
Response Type	no benefit
Approval Status	Phase II

Approval Status	Clinical Study
Response Type	decreased response
Evidence Type	Actionable

Indication/Tumor Type	follicular thyroid carcinoma
Response Type	sensitive
Approval Status	Preclinical - Cell culture

combination therapy	AZD6482 + NVP-AEW541
Indication/Tumor Type	melanoma
Response Type	no benefit

PTEN Gene Record

PTEN 5728 Clinically ActionableDrug Resistance

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

Interaction Types & Directionality: n/a

Interaction Info: combination therapy AZD8186 + Enzalutamide Evidence Type Actionable Approval Status Preclinical

PMIDs: 25544636

Sources: JAX-CKB CIViC

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type colon cancer Response Type sensitive Approval Status Preclinical

PMIDs: 25870146

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type uterine cancer Response Type decreased response Approval Status Preclinical

PMIDs: 25833835

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Evidence Type Actionable Approval Status Preclinical - Cell line xenograft Response Type sensitive

PMIDs: 21191045

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Ipatasertib + Paclitaxel Indication/Tumor Type triple-receptor negative breast cancer Response Type predicted – sensitive

PMIDs: 23287563 24141624 27872130 30037818

Sources: JAX-CKB CIViC

Interaction Types & Directionality: n/a

Interaction Info: combination therapy AZD8186 + BYL719 combination therapy AZD8186 + Enzalutamide combination therapy AZD8186 + BYL719 + Enzalutamide

PMIDs: 25544636 25514658

Sources: JAX-CKB OncoKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type melanoma Response Type sensitive Approval Status Preclinical - Cell line xenograft

PMIDs: 27196754 24387221

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type breast cancer Response Type resistant Approval Status Preclinical

PMIDs: 26839307

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type ovarian mucinous neoplasm Response Type decreased response Approval Status Preclinical

PMIDs: 24100628

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Evidence Type Actionable Approval Status Preclinical - Cell culture Response Type sensitive

PMIDs: 23705826

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Evidence Type Actionable Approval Status Preclinical - Cell culture Response Type predicted – sensitive

PMIDs: 28178345

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: combination therapy BMS-754807 + Dacomitinib Indication/Tumor Type glioblastoma multiforme Response Type sensitive

PMIDs: 25939761 26561558

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type Advanced Solid Tumor Response Type sensitive Approval Status Phase I

PMIDs: 26177599

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Idelalisib + MK2206 Indication/Tumor Type diffuse large B-cell lymphoma Response Type predicted – sensitive

PMIDs: 28178345

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type prostate cancer Response Type sensitive Approval Status Preclinical - Cell culture

PMIDs: 20797855

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Evidence Type Actionable Approval Status Preclinical - Cell line xenograft Response Type sensitive

PMIDs: 20371716

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type Advanced Solid Tumor Response Type sensitive Approval Status Preclinical - Cell culture

PMIDs: 22294718 26910118

Sources: JAX-CKB CIViC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: combination therapy GSK2636771 + LGX818 Indication/Tumor Type melanoma Response Type no benefit

PMIDs: 26117819 26645196 23674493 26577700

Sources: JAX-CKB MyCancerGenomeClinicalTrial OncoKB

Interaction Types & Directionality: n/a

Interaction Info: combination therapy GDC-0941 + MS417 Indication/Tumor Type breast cancer Response Type predicted – sensitive

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy AZD8186 + Enzalutamide

Evidence Type Actionable

Approval Status Preclinical

PMIDs:
25544636

Sources:
JAX-CKB CIViC

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type colon cancer

Response Type sensitive

Approval Status Preclinical

PMIDs:
25870146

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type uterine cancer

Response Type decreased response

Approval Status Preclinical

PMIDs:
25833835

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell line xenograft

Response Type sensitive

PMIDs:
21191045

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Ipatasertib + Paclitaxel

Indication/Tumor Type triple-receptor negative breast cancer

Response Type predicted – sensitive

PMIDs:
23287563 24141624 27872130 30037818

Sources:
JAX-CKB CIViC

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy AZD8186 + BYL719

combination therapy AZD8186 + Enzalutamide

combination therapy AZD8186 + BYL719 + Enzalutamide

PMIDs:
25544636 25514658

Sources:
JAX-CKB OncoKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type melanoma

Response Type sensitive

Approval Status Preclinical - Cell line xenograft

PMIDs:
27196754 24387221

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type breast cancer

Response Type resistant

Approval Status Preclinical

PMIDs:
26839307

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type ovarian mucinous neoplasm

Response Type decreased response

Approval Status Preclinical

PMIDs:
24100628

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell culture

Response Type sensitive

PMIDs:
23705826

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell culture

Response Type predicted – sensitive

PMIDs:
28178345

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy BMS-754807 + Dacomitinib

Indication/Tumor Type glioblastoma multiforme

Response Type sensitive

PMIDs:
25939761 26561558

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type sensitive

Approval Status Phase I

PMIDs:
26177599

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Idelalisib + MK2206

Indication/Tumor Type diffuse large B-cell lymphoma

Response Type predicted – sensitive

PMIDs:
28178345

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type prostate cancer

Response Type sensitive

Approval Status Preclinical - Cell culture

PMIDs:
20797855

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell line xenograft

Response Type sensitive

PMIDs:
20371716

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type sensitive

Approval Status Preclinical - Cell culture

PMIDs:
22294718 26910118

Sources:
JAX-CKB CIViC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

combination therapy GSK2636771 + LGX818

Indication/Tumor Type melanoma

Response Type no benefit

PMIDs:
26117819 26645196 23674493 26577700

Sources:
JAX-CKB MyCancerGenomeClinicalTrial OncoKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy GDC-0941 + MS417

Indication/Tumor Type breast cancer

Response Type predicted – sensitive

PMIDs:
9661880 22693356 19276360 24265153 23136191 24322983 27020857 26577700 26733612 28119489 26058079

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Navitoclax + ONC201

Indication/Tumor Type glioblastoma multiforme

Response Type sensitive

PMIDs:
26474387

Sources:
JAX-CKB

combination therapy	AZD6482 + Niraparib
combination therapy	AZD6482 + Talazoparib
combination therapy	AZD6482 + Olaparib

Indication/Tumor Type	uterine corpus sarcoma
Response Type	sensitive
Approval Status	Preclinical - Cell line xenograft

combination therapy	Gefitinib + Linsitinib
Indication/Tumor Type	glioblastoma multiforme
Response Type	sensitive

Indication/Tumor Type	ocular melanoma
Response Type	predicted – sensitive
Approval Status	Phase I

combination therapy	BKM120 + Trastuzumab
Indication/Tumor Type	Her2-receptor positive breast cancer
Response Type	predicted – sensitive

Indication/Tumor Type	ovarian clear cell adenocarcinoma
Response Type	sensitive
Approval Status	Preclinical - Cell line xenograft

combination therapy	DETD-35 + Vemurafenib
Approval Status	Preclinical - Cell line xenograft
combination therapy	SAR260301 + Vemurafenib

combination therapy	GDC-0941 + PLX4720
Indication/Tumor Type	melanoma
Response Type	sensitive

combination therapy	Abiraterone + Ipatasertib
Indication/Tumor Type	prostate cancer
Response Type	sensitive

combination therapy	MLN0128 + PD-0325901
Indication/Tumor Type	colorectal cancer
Response Type	no benefit